FY2025 Earnings Forecast for VRTX Issued By William Blair

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at William Blair increased their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued on Thursday, December 19th. William Blair analyst M. Minter now expects that the pharmaceutical company will earn $16.65 per share for the year, up from their prior estimate of $16.61. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.83) per share.

Several other research analysts have also issued reports on VRTX. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. UBS Group upped their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. HC Wainwright cut their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a research note on Friday. Finally, Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $499.77.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $397.27 on Monday. The business has a 50 day simple moving average of $470.41 and a 200 day simple moving average of $475.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The company has a market capitalization of $102.31 billion, a PE ratio of -199.63 and a beta of 0.36. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.67 earnings per share.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of VRTX. State Street Corp raised its position in shares of Vertex Pharmaceuticals by 0.8% during the 3rd quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock valued at $5,495,501,000 after acquiring an additional 90,173 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after purchasing an additional 851,054 shares during the period. Wellington Management Group LLP increased its holdings in Vertex Pharmaceuticals by 17.2% in the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock valued at $2,231,858,000 after purchasing an additional 704,421 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Vertex Pharmaceuticals by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock valued at $1,351,385,000 after buying an additional 159,693 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in Vertex Pharmaceuticals by 4.1% during the third quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company’s stock worth $1,170,506,000 after buying an additional 100,114 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.